The Institute for Clinical and Economic Review (ICER) has issued its first annual report on unsupported price increases for US drugs. The report found that 3 brand-name biologics that have FDA-approved biosimilars—adalimumab, rituximab, and pegfilgrastim—have had significant price increases that were not supported by new clinical evidence.
The Institute for Clinical and Economic Review (ICER) has issued its first annual report on unsupported price increases for US drugs. The report found that 3 brand-name biologics that have FDA-approved biosimilars—adalimumab, rituximab, and pegfilgrastim—have had significant price increases that were not supported by new clinical evidence.
“The norm in the United States has been for most pharmaceutical manufacturers to increase prices year after year—even accounting for the discounts they give insurers, and even for drugs that already sit at the top of the chart of spending for drugs in the US,” said David Rind, MD, ICER’s chief medical officer, in a statement, adding that the new report can help provide policy makers with an independent approach to determining whether price increases can be supported by new data.
In its analysis, ICER ranked the top 100 drugs by US sales revenue, and evaluated whether their prices, after accounting for rebates and concessions, were more than twice the level of growth in the medical consumer price index from 2017 to 2018. The ICER team then evaluated whether any relevant new evidence had emerged for these drugs over the past 3 years that could support a price increase.
They found that there were 7 drugs that had price hikes without adequate data to support the new costs, and the product that had the price increase with the greatest impact on US spending was the brand-name adalimumab, Humira.
With its 19.1% increase in its wholesale acquisition cost (WAC) from the end of 2016 to the end of 2018, and an estimated 15.9% net price increase over the same period, ICER estimates that increases to Humira’s price cost the United States $1857 million between 2017 and 2018.
The drug whose price hikes had the second greatest impact on spending was brand-name rituximab, Rituxan. With a 17.0% increase in WAC and a 23.6% estimated increase in net price, Rituxan was responsible for a US spending impact of $806 million.
A third biologic with approved biosimilars that saw its prices rise without support was brand-name pegfilgrastim, Neulasta. Pegfilgrastim came in fifth in terms of its impact on US spending, with a 14.6% WAC increase, an estimated 13.4% net price increase, and a $489 million increase in spending.
The other drugs identified by ICER as having unsupported price increases were pregabalin (Lyrica), tenofovir disoproxil fumarate (Truvada), tadalafil (Cialis), and dimethyl fumarate (Tecfidera).
While Humira has 4 FDA-approved biosimilars, no products are set to launch in the US market until 2023 as a result of patent settlements between Humira-maker AbbVie and biosimilar developers. In the case of Rituxan, 2 products have been approved by the FDA, but no launch date has been disclosed for either one. Neulasta currently faces US market competition from Coherus BioScience’s Udenyca and Mylan and Biocon’s Fulphila.
Challenges and Guidance in Biosimilar Assessment: An ISPOR Report on HTA Agency Approaches
May 14th 2024The ISPOR report highlights the urgent need for clear guidance on when and how to conduct health technology assessments (HTAs) for biosimilars, emphasizing the challenges faced by HTA agencies and the evolving role of HTAs in evaluating biosimilar value.
Biosimilars Policy Roundup for April 2024—Podcast Edition
May 5th 2024On this episode of Not So Different, The Center for Biosimilars® glances back at all the major biosimilar policy updates from April, including 2 FDA approvals, 1 European approval, and several insights into possible policy changes from the Festival of Biologics USA conference.
A New Chapter: How 2023 Will Shape the US Biosimilar Space for 2024 and Beyond
December 31st 2023On this episode of Not So Different, Cencora's Brian Biehn and Corey Ford take a look back at major policy and regulatory advancements in 2023 and how these changes will alter the space going forward.
Dr Sophia Humphreys Provides Calls to Action to Ensure Biosimilar Market Sustainability
April 30th 2024During her presentation during Festival of Biologics USA, Sophia Humphreys, PharmD, director of formulary management at Sutter Health, gave an overview of current challenges and opportunities for the biosimilar market and offered calls to action for multiple stakeholders.